Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Other Non-Current Liabilities: 2019-2021

Historic Other Non-Current Liabilities for Pharming Group N.V (PHAR) over the last 1 years, with Dec 2021 value amounting to -$25,000.

  • Pharming Group N.V's Other Non-Current Liabilities fell 20.64% to -$25,000 in Q4 2021 from the same period last year, while for Dec 2021 it was -$25,000, marking a year-over-year decrease of 20.64%. This contributed to the annual value of -$25,000 for FY2021, which is 20.64% down from last year.
  • Pharming Group N.V's Other Non-Current Liabilities amounted to -$25,000 in Q4 2021, which was down 0.00% from -$25,000 recorded in Q3 2021.
  • Pharming Group N.V's Other Non-Current Liabilities' 5-year high stood at -$20,722 during Q4 2020, with a 5-year trough of -$25.0 million in Q2 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was -$9.9 million (2019), whereas its average is -$10.9 million.
  • As far as peak fluctuations go, Pharming Group N.V's Other Non-Current Liabilities soared by 99.90% in 2020, and later fell by 20.64% in 2021.
  • Quarterly analysis of 3 years shows Pharming Group N.V's Other Non-Current Liabilities stood at -$19.8 million in 2019, then soared by 99.90% to -$20,722 in 2020, then declined by 20.64% to -$25,000 in 2021.
  • Its Other Non-Current Liabilities stands at -$25,000 for Q4 2021, versus -$25,000 for Q3 2021 and -$25.0 million for Q2 2021.